. Author manuscript; available in PMC: 2022 May 1.

Published in final edited form as: Crit Care Med. 2021 May 1;49(5):828–837. doi: 10.1097/CCM.0000000000004891

Table 3.

Hemoglobin association with outcome (mRS ≥4) at 3-month after ICH.

Study or Analysis Strategy	All patients (N=4,172)		Lobar (N=976)		Non-Lobar (N=3,167)
Study or Analysis Strategy	OR (95%CI)	P value	OR (95%CI)	P value	OR (95%CI)	P value
Study-specific results
ATACH-2	0.88 (0.79–0.99)	0.028	0.68 (0.47 – 0.98)	0.04	0.90 (0.80 – 1.01)	0.09
ERICH	0.93 (0.88–0.98)	0.01	0.94 (0.85 – 1.04)	0.23	0.92 (0.86 – 0.98)	0.01
FAST	0.95 (0.84–1.07)	0.37	1.01 (0.69 – 1.49)	0.95	0.92 (0.81 – 1.05)	0.21
Combined analyses
One-stage IPD meta-analysis	0.93 (0.88–0.98)	0.006	0.93 (0.75 – 1.14)	0.47	0.92 (0.87 – 0.98)	0.007
Two-stage IPD meta-analysis (Fixed Effects)	0.93 (0.89–0.97)	0.0007	0.93 (0.85 – 1.02)	0.10	0.92 (0.87 – 0.97)	0.001
Two-stage IPD meta-analysis (Random Effects)	0.92 (0.86–0.99)	0.039	0.89 (0.56 – 1.40)	0.37	0.92 (0.90 – 0.94)	0.003

Abbreviations: ATACH-2=Antihypertensive Treatment of Acute Cerebral Hemorrhage-II trial. ERICH=Ethnic/Racial Variations of Intracerebral Hemorrhage study. FAST=Recombinant Factor VIIa in Acute Intracerebral Haemorrhage trial. OR=Odds Ratio. 95%CI= 95% confidence interval. IPD=Individual participant data.

Missing data for ICH location = 29. Models adjusted by age, sex, race, ICH location (except in stratified analyses by location), ICH volume, presence of IVH, Glasgow Coma Scale and, in ERICH, anticoagulation use. Heterogeneity (all patients): tau2 = 0.0003, I2 = 0.0%, Q=0.85 (p=0.65). Heterogeneity (lobar): tau2 = 0.0216, I2 = 33.2%, Q=2.99 (p=0.22). Heterogeneity (nonlobar): tau2 = < 0.0001, I2 = 0.0%, Q=0.07 (p=0.97).